Health & Biotech
Respiri Limited (ASX: RSH) are an Australian owned company with smart tools to empower people with asthma and improve outcomes.
Backed by over twenty years of research by respiratory specialists, and with first-move advantage, Respiri offers an over-the-counter monitoring solution that will help people manage asthma in ways that have never been available before.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Check Up: Samsung and Big Pharma give big thumbs up to biotech sector
Health & Biotech
Who’s carrying on the Cochlear legacy? The ASX med device stocks that could soar from tailwinds
Health & Biotech
ASX Health Stocks: Clinuvel reveals study results, and Cann’s Mildura cannabis facility is a go
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: PIQ leaps 9pc on blood test results; Respiri gains 6pc on Wheezo order
Health & Biotech
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
News
10 at 10: These ASX stocks have given shareholders something to cheer about this morning
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
Respiri shares rise after TerryWhite Chemmart agrees to stock wheezo devices in pharmacies
News
10 at 10: These ASX stocks have begun the trading day in style this morning
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
Respiri to launch remote patient monitoring trial in Australia
Health & Biotech
Respiri announces strategic Advisor appointments as it pushes for global rollout of Wheezo
News
Market highlights and 5 ASX small caps to watch on Thursday
Health & Biotech
Watershed moment as Respiri’s wheeze-detecting device approved for OTC sale in USA
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech